GLP-1受体激动剂(GLP-1RA)在降糖的同时更能带来明确的心血管获益,即主要心血管不良事件发生风险显著降低,引领了糖尿病管理从血糖管理到整体化管理的治疗理念改变,更成为国内外指南一致推荐的ASCVD合并2型糖尿病(T2DM)全程治疗的一线药物。 为进一步探讨GLP-1 RA在临床中的应用,“第二届诺和诺德心血管代谢峰会”(NNC...
4月6日,华西医院内分泌代谢科李舍予等联合国内外多名学者发表在BMJ上的一项系统综述和网络Meta分析表明,在13类治疗糖尿病的药物中,除了钠葡萄糖共转运蛋白2抑制剂(SGLT2i)和胰高血糖素样肽1受体激动剂(GLP-1 RA)有明确的心肾益处外,非甾体盐皮质激素受体拮抗剂(MRA)非奈利酮也有类似的获益。 分析显示,SGLT2i...
Scale Synthesis of an Akt Kinase Inhibitor. Organic Process Research & Development , 16, 1069−1081(2012)[8] Peptide-compoud cyclization method（肽类化合物环合的方法）US20240166689A1[9] Base composition and Drug composition for external use.（基础成分与外用药成分）JPS58164520A[10] Drug ...
点击上方的 行舟Drug ▲ 添加关注 中国获批上市 2019年2月26日,礼来制药的GLP-1受体激动剂(RA)周制剂度易达®(度拉糖肽)(Dulaglutide)正式获得国家药品监督管理局(NMPA)批准进入中国,适用于成人2型糖尿病患者的血糖控制,包括单药以及接受二甲双胍和/或磺脲类药物治疗血糖仍控制不佳的患者。 以中国患者人群为主...
(2) the aggressive prosecution of bad actors who are illegally trafficking counterfeit or adulterated GLP-1 RA products, and (3) an independent task force outside of the FDA be charged with the final determination for adding or removing a drug from the “drug shortages” list w...
●Food and Drug Administration (FDA):美国食品药品监督管理局 ●European Medicines Agency (EMA):欧洲药品管理局 02 药政事务与合规 Regulatory Affairs and Compliance ●Regulatory Affairs (RA):药政事务 ●Market Authorization (MA):上市许可 ●post-appro...
在合成如下所示的一种GLP-1受体激动剂类的药物时,其中间体由A到B的酰胺键酸性水解反应,在DMI的促进下进行,效果较好。[6] 图片来源:参考文献6 6.肼置换反应 文献[7]则报道了在一项Akt激酶抑制剂的合成试验中,以DMI为溶剂,成功地实现了公斤级的肼置换反应,在DMI的作用下,6-氯-3-苯基-1,5-萘啶-2(1H)-...
Drug Interactions When initiating Ozempic®, consider reducing the dose of concomitantly administered insulin secretagogue (such as sulfonylureas) or insulin to reduce the risk of hypoglycemia Ozempic®causes a delay of gastric emptying and has the potential to impact the absorption of concomitantly ...
composition and Drug composition for external use.（基础成分与外用药成分）JPS58164520A[10] Drug ...
As used herein, the terms “active pharmaceutical ingredient”, “active agent”, “active ingredient”, “active substance”, “therapeutically active compound” and “drug” are meant to be synonyms, i.e., have identical meaning. In accordance with the present invention, an active pharmaceutical...